BioMarin Pharmaceutical: Barclays raises target price to $114 from $111
BMRN•Barclays raised its target price for BioMarin Pharmaceutical to $114 from $111.
Related News
Aeva schedules third-quarter 2026 results call
AEVA•
Innovative Industrial Properties: Stifel initiates coverage with buy rating, $56.25 target
IIPR•
Figma, Inc.: Stifel cuts target price to $22 from $25
FIG•
Trade conflicts cost prosperity around the world, German finmin says
SPY•
Seyond joins Dell and NVIDIA booth with live LiDAR operational twin demo at Smart City Expo World Congress 2026
NVDA•